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Abstract 
PCD is a rare autosomal recessive disorder of ciliary function. It is characterised by progressive 
sino-pulmonary disease, fertility problems and disorders of organ laterality. Clinical phenotype 
and disease course can vary significantly. A daily chronic wet cough that never goes away is 
invariably present, with most suffering from persistent and significant rhinosinusitis.  Middle ear 
effusion and hearing difficulty are seen in a proportion of patients. Bronchiectasis is reported in 
approximately 70% of children. 
Diagnosis can be difficult requiring specialist centre input. In patients with a suggestive clinical 
phenotype a combination of nasal nitric oxide, high-speed video microscopy analysis for ciliary 
beat frequency and pattern, and transmission electron microscopy analysis of ciliary 
ultrastructure are performed as appropriate. In populations studied genetic defects have been 
identified in approximately 60% of cases, with many genes yet to be discovered.  
There is no evidence on which to base guidelines of clinical management and most treatment 
regimens are extrapolated from those used in Cystic Fibrosis. Specialist care by respiratory and 
ENT specialists is recommended. Current respiratory management focuses on physiotherapy 
and exercise to help compensate for defective mucociliary transport together with identification 
and treatment of infection.  
On going international collaboration is key in being able to better understand a disease of such 
heterogeneity and to produce best practice guidance for standardised clinical care. 
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Defining the disease 
Primary Ciliary Dyskinesia (PCD) is a rare autosomal recessive disorder characterized by 
abnormal ciliary function, leading to progressive sino-pulmonary disease, reduced fertility 
and disorders of organ laterality.  The prevalence of PCD is approximately 1:20,000 live 
births although this varies significantly between ethnic groups. A prevalence of 1:2,200 has 
been reported in a highly consanguineous UK Asian population.  
Large numbers of ciliated cells are present in the respiratory tract, brain ventricles and 
aqueducts, testicular efferent ducts and fallopian tubes. Ciliated cells are the dominant cell 
type in human airways (up to 109 cilia per cm2). Normal cilia have 9 peripheral microtubular 
doublets and a central pair arrangement. The key axonemal components are the outer 
dynein arms and inner dynein arms, motors and radial spokes and the nexin dynein 
regulatory complex. Each cilium will beat in a coordinated fashion over a million times each 
day, providing mucociliary clearance and innate lung defence.  In PCD, mucociliary clearance 
is absent or markedly impaired due to abnormal ciliary movement. Reduced Generation of 
Multiple Motile Cilia (previously known as Ciliary Aplasia), is a rare disease entity, currently 
grouped with PCD, in which there are highly reduced numbers of cilia that can either be 
motile or have motility defects. Patients with this condition appear to present with a more 
severe clinical course of recurrent and chronic airway infection. 
Situs Inversus totalis occurs in approximately 45% of confirmed cases of PCD but is not seen 
in patients with central microtubular defects such as ciliary transposition. Kennedy and 
colleagues (2007) reported 6.3% of patients to have heterotaxy (as defined by any thoraco-
abdominal asymmetry other than situs inversus). In this group, there is a small but 
significant increase in prevalence of complex congenital heart disease. Rare associations of 
PCD include hydrocephalus, polycystic kidney disease and retinitis pigmentosa. The sperm 
tail has a similar structure and motor system to that of cilia. As a result, males with PCD will 
have marked sub-fertility or infertility. In women, defective ciliary function affecting the 
reproductive tract may sometimes affect fertility and potentially increase the risk of ectopic 
pregnancies. 
 
Course of the disease 
Primary Ciliary Dyskinesia is a genetically heterogeneous condition with variable clinical 
phenotypes. Patients invariably present with chronic rhino-sinusitis, a daily wet sounding 
cough, recurrent pulmonary infections and inflammation of the respiratory tract. Glue ear is 
very common and can cause significant hearing loss in young children. In 2014, Dell and 
colleagues reported that 91% of their PCD population had a history of neonatal respiratory 
distress. This is much higher than the UK experience.  
Radiological features of PCD are characterised by bronchiectasis, peri-bronchial thickening, 
mucous plugging, consolidation and air trapping. Bronchiectasis is more predominant in the 
middle and lower lobes and Magnin and colleagues (2012) reported evidence of 
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bronchiectasis in 70% of children on first CT scan (mean age 8.7 years). The true prevalence 
of structural lung disease in this age group remains unclear as not all children with PCD have 
CT scans.   
Abnormal lung function is common in PCD and is associated with an obstructive pattern 
with a reduction in both FEV1 and FEF25-75. A systematic review by Goutaki and colleagues 
(2015) reported a mean FEV1% of 58% (range 35-77%) and 78% (range 73-88%) in adults 
and children respectively.    
The natural history and disease progression of PCD is poorly defined with conflicting reports 
in the literature describing a wide variability in longitudinal change in lung function and 
disease progression. Marthin and colleagues (2010) assessed the change in lung function in 
74 patients. Over a three-year study period, 34% of patients lost more than 10 % of FEV1, 
57% were stable, and 10% improved by more than 10%. An earlier report from the same 
centre by Ellerman and Bisgaard (1997) reported lung function was maintained over many 
years following diagnosis in both children and adults. These variations in the course of lung 
function did not correlate with age of diagnosis or baseline lung function. In a UK report of 
151 adults, Shah and colleagues (2016) reported a decline of 0.49% predicted FEV1 per year 
in adult patients, compared with 5.6% and 2.35% in subjects with cystic fibrosis and non-CF 
bronchiectasis respectively. Deterioration in lung function occurs in some individuals before 
diagnosis and it appears this can be stabilised with appropriate treatment.  
In adult patients there is a wide spectrum of lung function impairment and radiological 
disease severity. Expert opinion suggests poor correlation between CT findings and 
spirometry, (Maglione (2012)). Lung clearance index is an alternative and more sensitive 
marker of airways disease in conditions such as cystic fibrosis. However in PCD, lung 
clearance index does not appear to correlate with either spirometry or high resolution CT 
findings. Further work is required to determine its place in assessment. 
Shah and colleagues (2016) found that Pseudomonas aeruginosa colonisation may be a 
marker of disease severity, rather than a predictor of disease progression. Colonisation is 
shown to correlate with age, impairment in FEV1 at diagnosis and extent of bronchiectasis, 
but did not correlate with change in lung function over time. These findings differ to those 
of the clinical course of cystic fibrosis. P. aeruginosa colonisation appears much less 
common in patients with PCD than with cystic fibrosis. Alanin and colleagues (2015) found 
39% of 107 patients with PCD met the criteria for chronic P.aeruginosa infection at least 
once. In contrast, by adulthood, approximately 80% patients with cystic fibrosis are 
colonised with P.aeruginosa. 
The prognosis of PCD varies significantly and children can develop severe lung disease. A 
study by Noone and colleagues (2003) evaluated 78 patients with PCD whose ages ranged 
between 0-73 years. While decline in lung function for the whole cohort was 25 to 50% less 
than that reported in cystic fibrosis, 25% of individuals were classified as having severe 
disease.  
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Diagnosis 
Unlike cystic fibrosis, newborn screening for PCD is not available and as such most 
presentations are as a result of the recognition of suggestive symptomatology. A diagnosis 
of PCD is often delayed due to lack of recognition of such signs and symptoms and diagnosis 
in adulthood is not uncommon, especially when situs inversus is not present. A European 
survey in 2010 by Kuehni and colleagues, reported median age at diagnosis to be 5.3 years, 
lower in children with situs inversus and in children attending tertiary respiratory centres.  
Diagnostic algorithms for PCD vary significantly between countries. There is no “gold-
standard” test for PCD, hence European consensus guidelines (2009) recommend a 
combination of tests including recognition of a clinical phenotype, nasal nitric oxide 
screening, high-speed video microscopy analysis of ciliary beat frequency and pattern, and 
transmission electron microscopy analysis of ciliary ultrastructure. The nationally funded 
diagnostic services for the UK (Leicester, Royal Brompton and Southampton) have used this 
approach since 2006. In addition they undertake ciliated cell culture to help in the diagnosis 
of rare or previously unreported phenotypes. Genetic testing is increasingly used but its 
availability in diagnostic testing varies significantly between countries.  
 
Clinical Phenotype 
The British Thoracic Society guidelines, (2008) define chronic cough in children as lasting 
more than 8 weeks. The most important clinical feature suggestive of a PCD diagnosis from 
a detailed history includes a wet sounding cough that has ‘always been there’ and is present 
every day even when the child is well. Most older children and adults will also expectorate 
sputum. Notably cough is present in the neonatal period. Table 1 highlights well-defined 
clinical features that may be present.   
Table 1. Important clinical features suggesting a diagnosis of PCD 
 
 
 
 
 
 
 
 
 
 Unexplained, prolonged neonatal respiratory distress 
 Recurrent airway infections 
 Persistent daily wet cough that ‘has always been there’ 
 Situs inversus 
 Persistent rhinorrhoea, often present from the neonatal period 
 Chronic sinusitis 
 Sibling or family member with PCD 
 Parental consanguinity 
 Chronic otitis media with effusion  
 Conductive hearing loss (often improving in teenage years) 
 Reduced fertility 
 Cardiovascular malformation 
 Polysplenia or asplenia 
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In children with chronic respiratory symptoms other causes should be considered and 
excluded as appropriate e.g. cystic fibrosis, immunodeficiency, structural airway 
abnormalities and aspiration. The differential diagnosis of chronic productive cough from 
the BTS guidelines 2008, are included in table 2:  
 Asthma 
 Post-nasal drip/ allergic rhinitis 
 Persistent endobronchial infection 
 Cystic Fibrosis 
 Immune Deficiency 
 Recurrent aspiration 
 Anatomical disorders including:  
 Tracheo/ bronchomalacia, airway 
compression, tracheoesophageal 
fistula or laryngeal cleft. 
 Retained inhaled foreign body 
 Psychogenic cough 
 Interstitial lung disease 
 Tuberculosis 
 Whooping cough 
 
In PCD chronic secretion retention in the upper respiratory tract predisposes to infection in 
the middle ear, nose and facial sinuses. Morgan and colleagues (2016) reported that chronic 
otitis media with effusion affects up to 80% of children and is often persistent, with 
fluctuation through adulthood. Hearing loss is common and is usually mild to moderate but 
can be profound. It does, however, usually spontaneously resolve in teenage years. Most 
centres do not recommend use of aural ventilation tube insertion, as prolonged ear 
discharge may ensue and persistent tympanic perforation may be seen. Nasal congestion is 
extremely common and nasal polyps can occur over time with chronic sinusitis, with 
impaired sense of smell reported by some. Chronic rhinosinusitis has a major impact on 
quality of life.  
Dell and colleagues (2016) showed that children with PCD had lower health-related quality-
of-life scores than children with cystic fibrosis, in comparing overall respiratory symptoms, 
of 63.7 and 77.8 respectively (scores 0-100). Interviews highlighted the importance of the 
impact of respiratory and sinus symptoms on daily living. Several items of significance in 
PCD included runny nose, nasal congestion, chronic otitis media, difficulty hearing, speech 
delay and in some cases, special accommodation in the classroom. 
A full clinical examination is important, including general health and nutrition status, and full 
ENT examination. Digital clubbing is uncommon in patients with PCD. Late recognition of 
dextrocardia is not uncommon due to failure to auscultate on the right side of the chest 
where the apex lies.  
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It can be difficult to determine if children with PCD are worse due to an infection as unlike 
most children with cystic fibrosis or bronchiectasis due to other causes whose cough 
disappears when well, the ‘PCD’ wet sounding cough never goes away.  Although chest X-
rays are requested in PCD they may be normal and do not exclude underlying 
bronchiectasis. As with other respiratory problems in childhood, spirometry is performed 
when the child is old enough, on a regular basis. A sputum sample or cough swab should be 
taken in order to determine microbiology and guide antibiotic therapy.  
 
Specific diagnostic Investigations 
 Several predictive tools have been developed to aid in earlier recognition and appropriate 
referrals to PCD centres. Investigators at seven North American sites in the Genetic 
Disorders of Mucociliary Clearance Consortium defined four clinical features to be 
statistically predictive of PCD. These included laterality defect; unexplained neonatal 
respiratory distress; early-onset, year-round nasal congestion; and early-onset, year-round 
wet cough. In the UK, Behan and colleagues (2016) developed a diagnostic prediction tool 
called PICADAR (PrImary CiliARy DyskinesiA Rule), which showed good sensitivity and 
specificity of 0.9 and 0.75 respectively.  
Listed below are the tests undertaken to help diagnose patients with PCD. 
 
Nasal Nitric Oxide 
High-speed video microscopy analysis and transmission electron microscopy are technically 
demanding investigations. Nasal nitric oxide has been established as a non-invasive 
screening tool for PCD and should be used as part of the diagnostic work-up. It can be 
measured in most, but not all children over 5 years of age and allows early assessment in 
respiratory units. Nasal obstruction or the inability to perform the test, are not uncommon 
reasons for failure.   
Nasal NO levels are low in the vast majority (usually <100 ppb), but not in all patients with 
PCD.  While emerging portable analysers have resulted in an increased access to nasal nitric 
oxide measurements, values fluctuate according to the equipment and technique used. 
There is no current consensus over exact thresholds to constitute cut off values.  
 
High-speed video microscopy analysis 
 
Ciliary function can be assessed by high-speed video microscopy analysis of ciliary beat 
frequency and ciliary beat pattern. The technique requires highly trained individuals 
experienced in recognising different beat patterns and has been adopted by many countries 
worldwide. The test can help identify patients with PCD in whom electron microscopy is 
normal and where a genetic defect has not been identified. Abnormalities of pattern 
associated with PCD include static, slow, rotating, stiff, hyper-frequent and vibrating cilia. 
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Subtle functional defects are increasingly recognised to cause disease. Reference ranges for 
ciliary beat frequency vary and in our laboratory, range between 10-15Hz. It is important 
that individual laboratories standardise their technique and obtain their own normal values. 
In 2009, Stannard and colleagues performed high-speed video microscopy analysis and 
electron microscopy on nasal tissue from 371 patients referred to Leicester Royal Infirmary 
for diagnostic assessment, in order to determine the ability of ciliary beat frequency and 
ciliary pattern analysis to predict electron microscopy-diagnosed PCD. High-speed video 
microscopy analysis was found to be highly sensitive and specific. The group recognised the 
existence of a phenotype where no ultrastructural abnormality could be detected on 
electron microscopy, ciliary beat frequency was high, but ciliary pattern analysis was 
abnormal. These findings highlight the continued need for a combination approach in the 
diagnostic process. 
Analysis of cilia can be particularly difficult due to secondary damage but this is vastly 
reduced if nasal brushings are taken 4 weeks or more after a viral upper respiratory tract 
infection. 
 
Transmission electron microscopy 
 
Transmission electron microscopy allows the visualisation of the ciliary ultrastructure. 
Correct identification of PCD ultrastructural defects requires highly trained and experienced 
staff and findings can be influenced by inflammation and infection of ciliated epithelium. 
Defects in ciliary components can cause cilia to be static or to beat dyskinetically. Lucas and 
colleagues (2016) reported that the most common defects affect the outer dynein arms and 
a combination of the inner and outer dynein arms. Inner dynein arm defects with 
microtubular disorganisation have been reported in approximately 15% of PCD cases. 
Isolated inner dynein arm defects are seen but currently no genetic mutations have been 
identified that cause this phenotype. Central pair and microtubular defects occur less 
frequently. 
Axonemal structural analysis by transmission electron microscopy remains an effective test 
for PCD as it is highly specific in confirming a diagnosis and shows an excellent correlation 
with genotype. Previous research has suggested that in up to 20% of PCD cases the 
axonemal structure looks normal, although in our experience the figure is lower. 
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Figure 1.  Typical transmission electron microscopy axonemal cross sections of normal cilia 
(A), and from patients with PCD: lack of dynein arms (B), lack of inner dynein arms (C), lack 
of outer dynein arms (D) and microtubule transposition defect (E). 
 
      A 
 
 
 
  
 
 
 
 
 
B   C   D   E 
 
 
 
 
 
Ciliated cell Culture 
Ciliated epithelium can be re-analysed following culture and re-differentiation of the 
epithelial cells using an air-liquid interface technique. In 2014, Hirst and colleagues showed 
that post-culture samples clarified the diagnostic status, and in a number of subjects, 
enhanced the ability to make a diagnosis. High-speed video micrsocopy results suggestive of 
PCD are confirmed either by repeat brushings or culturing of the epithelial cells and 
reanalysis.  
Although 2009 guidelines suggested potential adjuncts to diagnosis including 
immunofluorescence labelling of cilia proteins, radioaerosol mucociliary clearance and 
genotyping, they have not been incorporated into the UK diagnostic algorithm. 
Pulmonary radioaerosol MCC is described as a technique based on characterising the 
clearance patterns of inhaled radioaerosol tracer. This is however, non-specific to PCD and 
therefore of limited use as a diagnostic tool. 
Microtubular doublet 
Outer dynein arm complex 
Inner dynein arm complex 
Radial spoke 
Central microtubule doublet 
Cell membrane 
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Genetics 
PCD is inherited in an autosomal recessive fashion. In 1999 Pennarun and colleagues 
described the identification of the first PCD-causing genetic mutation. Since then there have 
been rapid advances in the understanding of the underlying genetic defects responsible for 
PCD.  To date, over 30 genes have been described as being associated with a PCD phenotype 
and this is felt to account for approximately 60% of diagnosed cases. It is interesting to 
reflect on the recent advances in mutation-specific therapy in cystic fibrosis, that this 
condition has mutations in one known gene and encompasses approximately 27 exons. PCD 
as mentioned is associated with mutations in at least 30 separate genes encompassing over 
700 exons.  With over 250 proteins in the cilium, (Ostrowski and colleagues, 2002), and 
additional proteins involved in the cytoplasmic assembly and or transport of dyneins, there 
is potential for a large number of gene mutations still to be identified. 
 
The association between genetic defects and ciliary ultrastructure and function are 
increasingly well established, although the links between genetics and clinical phenotype 
remain largely unknown. International data collection is underway in order to aid 
understanding and tailor individualised management. Current genotype and phenotype 
correlations have demonstrated that lung disease patterns appear variable across all ciliary 
ultrastructural and genotypic groups. Knowles and colleagues (2014), reported the 
association of biallelic mutations in RSPH1 while more mild disease and CCDC39/ CCDC40 
have been linked to more severe disease, as described by Davis and colleagues (2015). 
Table 3. A list of the more common genes affected in PCD and description of their 
mutational consequence within the ciliary axoneme or cell.   
Protein function Gene/protein name 
ODA proteins  DNAH5, DNAI1, DNAI2, DNAL1, NME8, 
DNAH11 
ODA-associated proteins that enable ODA 
docking and attachment to the axoneme 
CCDC114, CCDC151, ARMC4, TTC25, 
CCDC103 
Molecular ruler proteins CCDC39, CCDC40 
Nexin dynein regulatory complex proteins CCDC65, CCDC164, GAS8 
Central pair proteins HYDIN 
Radial spoke proteins RSPH1, RSPH3, RSPH4A, RSPH9, DNAJB13 
Cytoplasmic assembly of cilia DNAAF1, DNAAF2, DNAAF3, DNAAF4, 
DNAAF5, LRRC6, ZMYND10, SPAG1, 
C21orf59 
Multiciliogenesis proteins. Mutations 
associated with RGMC 
CCNO, MCIDAS  
 
ODA= Outer Dynein Arm, RGMC=Reduced Generation Motile Cilia  
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Mutation screening using multigene panels and next-generation sequencing allows 
genotyping and may help with the diagnosis with certain PCD phenotypes where 
ultrastructure is normal. 
 
Summary 
Accuracy of diagnostic testing was assessed by Jackson et al in 2016, using data from 654 
patients referred for PCD diagnostics. Their work highlighted the importance of a combined 
approach for diagnostic investigations. High-speed video microscopy alone had excellent 
accuracy, but required significant expertise and often repeated sampling or cell culture. 
Transmission electron microscopy alone was found to be specific but missed 21% of cases. 
Nasal nitric oxide (⩽30 nLmin−1) was useful in combination with high-speed video 
microscopy analysis. In isolation nasal nitric oxide screening at this cut-off would miss 
approximately 10% of cases. The group reported a high accuracy with combination testing 
which remains the requirement. Recent reports of PCD gene mutations associated with 
inconclusive high-speed video microscopy analysis or transmission electron microscopy 
studies highlights the need for highly skilled and experienced microscopists to ensure 
accurate diagnosis for this significantly heterogeneous disease, and also the increasing 
availability of genetic testing to aid in diagnostics. A current priority is in standardization of 
methods used and reporting of tests. Evidence-based guidelines for diagnostic testing are 
under development through the European Respiratory Society PCD Task Force.  
 
With the discovery of a growing number of mutations, patients with recognized genes can 
be offered genetic counselling and extended family screening in high-risk populations.  
 
Lack of awareness 
There is a lack of awareness of PCD among the medical profession. A study by Behan and 
colleagues (2016) reported patients experience on the diagnostic process of PCD. Thirty-five 
percent had visited their doctor on more than 40 occasions with symptoms prior to referral 
for PCD testing. Ninety-seven percent of patients considered it very important to improve 
awareness of PCD among medical practitioners.  
 
Management 
A national management service was set up in four UK centres in 2013. This is commissioned 
by the NHS to provide a specialist multidisciplinary team annual review and advice service 
for children in England.  Currently there is very limited evidence to base guidelines for the 
treatment of PCD and management has largely been extrapolated from other respiratory 
diseases, in particular cystic fibrosis. Given the different pathophysiology of PCD and cystic 
fibrosis, an evidence base for PCD management should be seen as a priority. 
Clinical evaluation of patients with PCD is difficult as patients almost invariably have a 
persistent wet sounding cough which contrasts with most children with cystic fibrosis or 
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non-CF bronchiectasis where the cough diminishes or clears completely with treatment. 
Clinical assessment relies on monitoring changes in cough and sputum production, clinical 
wellbeing, lung function and culture of pathogens. Deterioration in these parameters will 
often require antibiotic treatment and more intensive airway clearance. A major aim of 
treatment is to improve where possible and to maintain lung function. This involves 
approaches outlined below. 
 
Airway clearance 
Optimisation of mucociliary clearance is a cornerstone for current management strategies. 
There is presently no evidence to support the use of any particular airway clearance device 
or technique and physiotherapy should be tailored to the individual, which may aid 
compliance. Routine exercise is strongly encouraged. 
 
Mucolytics 
Both cystic fibrosis and PCD are associated with neutrophilic airway inflammation and the 
release of neutrophil DNA within secretions. In cystic fibrosis, there are multiple clinical 
trials showing significant improvement in lung function, quality of life and reduced 
pulmonary exacerbation following daily nebulisation of recombinant human rDNAse. It is 
not, however recommended in non-CF bronchiectasis as it has been found to be ineffective. 
It has not been formally studied in PCD.  
Hypertonic saline at 3-7% is recommended for use in cystic fibrosis. There is no evidence-
based research to support its use.  
 
Microbiology 
Polineni and colleagues (2016) suggested that sputum and cough swab specimens should be 
processed to the same standards and protocols as for cystic fibrosis specimens. This includes 
using the appropriate media and monitoring for bacteria such as Pseudomonas aeruginosa 
and atypical Mycobacteria. Staphylococcus aureus, Streptococcus pneumonia and non-
typeable Haemophilus influenza are often the predominant bacteria in the sputum of 
patients with PCD.  
 
There is no evidence supporting the use of inhaled antibiotics in PCD, although they are 
often tried based on evidence extrapolated from cystic fibrosis clinical trials. Eradication 
therapy is advised if P. aeruginosa is cultured. Data supporting the use of low-dose 
macrolides in non-CF bronchiectasis has resulted in the wide use of low dose Azithromycin 
although no trials have been undertaken in PCD.  
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Pneumococcal and annual influenza vaccines are recommended.  
 
Otitis media and hearing 
Chronic Otitis media with effusion, (glue ear) can significantly affect quality of life, hearing, 
language development and school performance. In the UK and Europe hearing aids are 
advocated for those with hearing defects as insertion of ventilation tubes appears to be 
associated with discharge from the ear and in some, persistent perforation of the eardrum. 
The natural history of hearing problems is for the majority to have considerable 
improvement in hearing during teenage years with many no longer requiring hearing aids. 
Chronic rhinosinusitis is a significant burden for patients. Sino-nasal irrigation, often 
referred to as nasal douching, can remove mucus, bacteria and biofilm from the sinuses and 
reduce oedema. Many patients report benefit but again research evidence of benefit is 
lacking. The use of topical steroids and antibiotics has not been evaluated. Evidence for the 
use of endoscopic sinus surgery in severe cases is also lacking.  
 
In Conclusion 
Research is clearly needed and due to small patient numbers the establishment of 
International PCD registries should facilitate evaluation of management options. 
International and multidisciplinary collaborations will be key to this. The USA based PCD 
foundation, investigators and clinicians are developing a network of PCD clinical centres to 
coordinate efforts in North America and Europe, in order to improve knowledge and care.  
The UK and USA website support groups are: 
 www.pcdsupport.org.uk 
 www.pcdfoundation.org 
 
Practice points 
 PCD is a progressive condition, which may result in significant morbidity. 
 A high index of suspicion is required in children with a persistent, wet sounding cough, that 
is present every day and who also have nasal symptoms, with or without situs anomalies.   
 PCD should be considered in a term neonate with unexplained, prolonged respiratory 
distress. 
 Diagnosis is often delayed, with evidence of bronchiectasis in children. 
 Children and adults need specialist respiratory and ENT care. This will also facilitate 
evidence-based trials on a multicentre basis. 
 There is an on-going requirement for international collaboration for evidence based disease 
management. 
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